Insider · CIK 0001699022
Douglas F Kling
cooofficer
Files at NAMS (NewAmsterdam Pharma Co N.V.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares | +16,539 | $0.00 | $0 | 60,539 | Mar 28, 2025 |
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares | -16,539 | - | - | 44,000 | Mar 28, 2025 |
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Restricted Stock Unitderivative | +16,539 | - | - | 16,539 | Mar 28, 2025 |
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Restricted Stock Unitderivative | -16,539 | - | - | 0 | Mar 28, 2025 |
| Mar 17, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares10b5-1 | +88,112 | - | - | 132,112 | Mar 19, 2025 |
| Mar 17, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares10b5-1 | +11,888 | $10.00 | $119k | 144,000 | Mar 19, 2025 |
| Mar 17, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -100,000 | - | - | 44,000 | Mar 19, 2025 |
| Mar 17, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Option (right to buy)derivative10b5-1 | -88,112 | $0.00 | $0 | 47,251 | Mar 19, 2025 |
| Mar 17, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Option (right to buy)derivative10b5-1 | -11,888 | $0.00 | $0 | 650,930 | Mar 19, 2025 |
| Feb 18, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares10b5-1 | +90,782 | - | - | 134,782 | Feb 20, 2025 |
| Feb 18, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -90,782 | - | - | 44,000 | Feb 20, 2025 |
| Feb 19, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares10b5-1 | +9,218 | - | - | 53,218 | Feb 20, 2025 |
| Feb 19, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -9,218 | - | - | 44,000 | Feb 20, 2025 |
| Feb 18, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Option (right to buy)derivative10b5-1 | -90,782 | $0.00 | $0 | 135,363 | Feb 20, 2025 |
| Feb 19, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Option (right to buy)derivative10b5-1 | -9,218 | $0.00 | $0 | 126,145 | Feb 20, 2025 |
| Jan 29, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares10b5-1 | +56,863 | - | - | 100,863 | Jan 31, 2025 |
| Jan 29, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -56,863 | - | - | 44,000 | Jan 31, 2025 |
| Jan 30, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares10b5-1 | +13,578 | - | - | 57,578 | Jan 31, 2025 |
| Jan 30, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -4,664 | - | - | 52,914 | Jan 31, 2025 |
| Jan 30, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -8,914 | - | - | 44,000 | Jan 31, 2025 |
| Jan 29, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Option (right to buy)derivative10b5-1 | -56,863 | $0.00 | $0 | 239,723 | Jan 31, 2025 |
| Jan 30, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Option (right to buy)derivative10b5-1 | -13,578 | $0.00 | $0 | 226,145 | Jan 31, 2025 |
| Jan 27, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares10b5-1 | +104,174 | - | - | 148,174 | Jan 29, 2025 |
| Jan 27, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -80,359 | - | - | 67,815 | Jan 29, 2025 |
| Jan 27, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -23,815 | - | - | 44,000 | Jan 29, 2025 |
| Jan 28, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares10b5-1 | +25,385 | - | - | 69,385 | Jan 29, 2025 |
| Jan 28, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -20,237 | - | - | 49,148 | Jan 29, 2025 |
| Jan 28, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares10b5-1 | -5,148 | - | - | 44,000 | Jan 29, 2025 |
| Jan 27, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Option (right to buy)derivative10b5-1 | -104,174 | $0.00 | $0 | 321,971 | Jan 29, 2025 |
| Jan 28, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Option (right to buy)derivative10b5-1 | -25,385 | $0.00 | $0 | 296,586 | Jan 29, 2025 |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Ordinary Shares | +44,000 | - | - | 44,000 | Jan 7, 2025 |
| Jan 2, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jan 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.